



Pancreatic Ductal Adenocarcinoma: From Pathophysiology to Novel Therapeutic Approaches 2.0

Guest Editors:

Prof. Dr. Rossano Lattanzio

Department of Innovative
Technologies in Medicine and
Dentistry, Center for Advanced
Studies and Technology (CAST),
University "G. d'Annunzio" Chieti-
Pescara, Chieti, Italy

Prof. Dr. Konstantinos Dimas

Department of Pharmacology,
School of Medicine, School of
Health Sciences, University of
Thessaly, Larisa, Greece

Deadline for manuscript
submissions:
closed (31 October 2022)

Message from the Guest Editors

Dear Colleagues,

Pancreatic cancer (PC) is one of the leading causes of cancer-related death worldwide, because of the propensity of the tumors to disseminate at an early stage, sustained by their complex microenvironment. At the time of diagnosis, only 20% of PC patients are eligible for surgical resection. Hence, there is an urgent need to find new therapeutic strategies that can be more specific and effective for treating PC patients. This Special Issue will provide insights regarding PC cells' molecular drivers, highlighting the impact of the tumor microenvironment on PC cells, and will discuss the implications for developing specific PC therapies. Authors are invited to submit their original research, communications, and review articles to this Special Issue of *Biomedicines*. Potential topics include, but are not limited to, the following:

- The role of cancer stem cells or tumor-initiating cells in the genesis and progression of PC
- The impact of the epigenetic changes in PC disease
- Pancreatic tumor microenvironment
- Role of the exosomes in PC
- Prognostic and predictive biomarkers in PC
- Novel targeted therapies in PC





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)